pmea

Adefovir is an acyclic nucleoside phosphonate that acts as a reverse transcriptase inhibitor used for treatment of hepatitis B and herpes simplex virus infection.

Adefovir diphosphate 2TEA is the salt form of Adefovir diphosphate.Adefovir diphosphate is a metabolite of Adefovir (GS-0393,PMEA) and cyclic nucleoside phosphonate (ANP) analog , an orally available reverse transcriptase inhibitor with antiviral activity against herpes, hepatitis B, and human immunodeficiency virus (HIV).

PMPMEase-IN L-23 is a novel prenylated methylated protein methylesterase inhibitor.

PMPMEase-IN L-28 is a novel inhibitor of prenylated methylated protein methylesterase.

Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.

Pradefovir mesylate (Hepavir B) is converted to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in human liver microsomes with Km of 60 μM.

Pradefovir (Remofovir) is a reverse transcriptase inhibitor potentially for treatment of chronic HBV infection. Pradefovir is also a liver-targeted prodrug of adefovir. After metabolic activation, Pradefovir was converted to PMEA (9-(2-phosphonylmethoxyethyl)adenine) in human liver microsomes with a K(m) of 60 microM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 ml/min.